KRT6A Monoclonal Antibody

Code CSB-MA949708
Size US$166
Order now
Image
  • IHC image of CSB-MA949708 diluted at 1:100 and staining in paraffin-embedded human cervical cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-mouse IgG polymer labeled by HRP and visualized using 0.05% DAB.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Mouse anti-Homo sapiens (Human) KRT6A Monoclonal antibody
Uniprot No.
Target Names
KRT6A
Alternative Names
CK-6A antibody; CK-6D antibody; CK6A antibody; CK6C antibody; CK6D antibody; Cytokeratin-6A antibody; Cytokeratin-6D antibody; K2C6A_HUMAN antibody; K6A antibody; K6C antibody; K6D antibody; keratin 6A antibody; Keratin antibody; Keratin; type II cytoskeletal 6A antibody; Keratin-6A antibody; Krt6a antibody; KRT6C antibody; KRT6D antibody; type II cytoskeletal 6A antibody; Type-II keratin Kb6 antibody
Raised in
Mouse
Species Reactivity
Human
Immunogen
Synthesized peptide derived from human Cytokeratin 6
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Clonality
Monoclonal
Isotype
IgG1, Kappa
Purification Method
The antibody was affinity-purified from mouse ascites by affinity-chromatography using specific immunogen.
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Form
Liquid
Tested Applications
ELISA, IHC
Recommended Dilution
Application Recommended Dilution
IHC 1:20-1:200
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Description

The production of the KRT6A monoclonal antibody involves the use of hybridoma technology. To obtain this KRT6A monoclonal antibody, B cells were isolated from the spleen of a mouse immunized with the synthesized peptide derived from human KRT6A and then fused with myeloma cells to create hybridoma cells. Hybridomas that secreted KRT6A antibodies were screened and then injected into the abdominal cavity of mice for culture. The resulting KRT6A monoclonal antibody was then purified from mouse ascites through affinity chromatography, using a specific immunogen, to ensure its purity. The purified KRT6A monoclonal antibody is suitable for use in ELISA and IHC applications and has been validated for its specificity towards human KRT14 protein.

KRT6A is specifically expressed in hair follicles, nails, and other keratinized epithelial tissues. It plays a key role in the formation and maintenance of hair shafts and is involved in hair growth and differentiation. Additionally, KRT6A has been implicated in wound healing and the response to various stresses, such as heat shock and oxidative stress. Mutations in KRT6A have been associated with hair disorders, such as pachyonychia congenita.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Epidermis-specific type I keratin involved in wound healing. Involved in the activation of follicular keratinocytes after wounding, while it does not play a major role in keratinocyte proliferation or migration. Participates in the regulation of epithelial migration by inhibiting the activity of SRC during wound repair.
Gene References into Functions
  1. Manipulating K6a phosphorylation or ubiquitin-proteasome system (UPS) activity may provide opportunities to harness the innate immunity of epithelia against infection. PMID: 29191848
  2. Several missense polymorphisms in KRT6A, KRT6B and KRT6C that lead to a higher risk for dental caries. PMID: 29357356
  3. KRT6A genetic mutation is associate with the development of Pachyonychia Congenita in patients in Australia. PMID: 27041546
  4. we here describe a family with pachyonychia congenita K6a, manifesting atypical symptoms of impaired wound healing and cheilitis. PMID: 24708461
  5. Keratin-derived antimicrobial peptides (KDAMPs) and their synthetic analogs exhibit antimicrobial activity against bacterial pathogens. PMID: 23006328
  6. Genotype-phenotype correlations among PC patients with codon-125 mutation in KRT16 were established, while the phenotypes caused by the IVS8-2A>C mutation in KRT6A need further studies to confirm the rare feature of fissured tongue PMID: 22668561
  7. We observed a higher likelihood of oral leukokeratosis in individuals harboring KRT6A mutations. PMID: 22264670
  8. Phenotypic differences exist between KRT6A and KRT16 mutations support adoption of a new classification system. PMID: 22098151
  9. This report is the first case of pachyonychia congenita with laryngeal obstruction in which the gene mutation has been established (a deletional mutation in keratin 6a). PMID: 21554383
  10. Focal palmoplantar keratoderma is associated with mutations in keratin K6c in 3 families. 2 unrelated families have Asn172 del and the other has a deletion of AA 462-470. Review. PMID: 20470930
  11. these data highlight the possibility of a physiological role for K6/K16 heterodimers in keratinocyte cell migration, in addition to the heterodimer's known functions in cell differentiation and mechanical resilience. PMID: 20403371
  12. The mutation of 521T--> C in the K6A gene is the causing mutation in pachyonychia congenita type I. PMID: 20140871
  13. Mutations Y465H and N171D of the KRT16A gene were detected in the sporadic pachyonychia congenita cases. PMID: 19806570
  14. Four new missense and five known mutations in K6a, one new deletion and three previously identified missense mutations in K16, plus one known mutation in K17 are reported in pachyonychia congenita. PMID: 17719747
  15. PC-1 is due to mutations of the KRT16 gene or its expression partner KRT6A, wheres PC-2 is caused by mutations in the KRT17 or KRT6B genes. PMID: 18489596
  16. Three novel and four recurrent keratin 6A (KRT6A) mutations were found in Chinese patients with pachyonychia congenita type 1 PMID: 19416275
  17. Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients. PMID: 19699613

Show More

Hide All

Involvement in disease
Pachyonychia congenita 3 (PC3)
Protein Families
Intermediate filament family
Tissue Specificity
Expressed in the corneal epithelium (at protein level).
Database Links

HGNC: 6443

OMIM: 148041

KEGG: hsa:3853

STRING: 9606.ENSP00000369317

UniGene: Hs.700779

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*